Share capital [Text Block] | 7. Share capital Authorized: unlimited common shares, no par value Number of shares Ascribed value November 30, 2016 105,286,469 136,357 Exercise of options 188,856 85 Restricted Share Units 209,198 83 November 30, 2017 105,684,523 136,525 Bought deal financing 24,784,482 28,750 Share issuance costs - (1,819) Exercise of options 79,453 34 Restricted Share Units 800,000 457 May 31, 2018, issued and outstanding 131,348,458 163,947 On April 20, 2018, the Company completed a bought-deal financing for gross proceeds of $ 28.7 24,784,482 1.16 1.8 26.9 As of May 31, 2018, 20,685 3,447 (a) Stock options During the period ended May 31, 2018, 2,125,000 1,695,000 1.04 0.72 0.37 For the period ended May 31, 2018, Trilogy recognized a stock-based compensation charge of $ 0.58 0.27 The fair value of the stock options recognized in the period has been estimated using the Black-Scholes option pricing model. Assumptions used in the pricing model for the period are as provided below. May 31, 2018 Risk-free interest rates 1.55 % Exercise price CAD$ 1.04 Expected life 3.0 years Expected volatility 77.6 % Expected dividends Nil As of May 31, 2018, there were 1,403,342 0.96 0.25 A summary of the Company’s stock option plan and changes during the six month period ended is as follows: May 31, 2018 Number of options Weighted average Balance beginning of the year 7,127,500 0.54 Granted 2,125,000 0.80 Exercised (135,844) 0.59 Forfeited (25,000) 1.53 Balance end of period 9,091,656 0.59 The following table summarizes information about the stock options outstanding at May 31, 2018. Outstanding Exercisable Unvested Range of price Number of Weighted Weighted Number of Weighted Number of $0.34 to $0.50 4,169,989 2.20 0.40 4,169,989 0.40 $0.51 to $1.00 4,746,667 3.40 0.74 3,413,325 0.75 1,333,342 $1.01 to $1.49 175,000 3.83 1.19 105,000 1.25 70,000 9,091,656 2.60 0.59 7,688,314 0.57 1,403,342 The aggregate intrinsic value of vested share options (the market value less the exercise price) at May 31, 2018 was $ 5.9 1.2 0.1 0.31 (b) Restricted Share Units and Deferred Share Units The Company has a Restricted Share Unit Plan (“RSU Plan”) and a Non-Executive Director Deferred Share Unit Plan (“DSU Plan”) to provide long-term incentives to employees, officers and directors. Awards under the RSU Plan and DSU Plan may be settled in cash and/or common shares of the Company at the Company’s election with each restricted share unit (“RSU”) and deferred share unit (“DSU”) entitling the holder to receive one common share of the Company or equivalent value. All units are accounted for as equity-settled awards. Number of RSUs Number of DSUs Balance beginning of the year 600,002 1,041,231 Granted 600,000 95,398 Vested/paid (800,000) - Balance end of period 400,002 1,136,629 For the six months ended May 31, 2018, Trilogy recognized a stock-based compensation charge of $ 0.49 0.22 As part of the annual incentive payout for the 2017 fiscal year, 300,000 300,000 800,000 800,000 (c) Share Purchase Warrants Number of Years to expiry Exercise price Balance beginning of the year 6,521,740 1.60 1.60 Balance end of period 6,521,740 1.10 1.52 The exercise price of the share purchase warrants was adjusted downward as a result of the financing completed on April 20, 2018 from $ 1.60 1.52 90,000 July 2, 2019 |